Cue Biopharma to Host Business Update Call and Webcast

Rhea-AI Summary

Cue Biopharma (CUE) has announced a conference call and webcast scheduled for May 17, 2021, at 4:30 p.m. EDT to share a business update. This includes a clinical update on the ongoing Phase 1a/1b trial of CUE-101, with emphasis on a confirmed partial response in a patient treated for HPV+ recurrent/metastatic head and neck squamous cell carcinoma. The management will also discuss recent advancements in their technology platform and strategic objectives. Investors can access the event via the company's website.

CAMBRIDGE, Mass., May 10, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells directly within the patient’s body, announced today it will host a conference call and webcast to provide a business update on Monday, May 17, 2021 at 4:30 p.m. EDT. Live and archived versions of the event can be accessed via the Company’s website.

Members of the Cue Biopharma executive management team will provide a clinical update from the Company’s ongoing Phase 1a/1b monotherapy dose escalation clinical trial of CUE-101, including discussing the confirmed partial response (PR) recently reported in one patient receiving CUE-101 as second-line treatment for HPV+ recurrent/metastatic head and neck squamous cell carcinoma. Management will also provide an update on the Company’s most recent technology platform developments and pipeline progress as well as updates on its strategic objectives and anticipated milestones.

Webcast Details
Monday, May 17, 2021 at 4:30 p.m. EDT

Investors: 855-327-6837
International: 631-891-4304
Conference ID: 10014734
Webcast: http://public.viavid.com/index.php?id=144898

About Cue Biopharma
Cue Biopharma, a clinical-stage biopharmaceutical company, is engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells directly within the patient’s body to transform the treatment of cancer, infectious disease and autoimmune disease. The company’s proprietary platform, Immuno-STAT™ (Selective Targeting and Alteration of T cells) is designed to harness the body’s intrinsic immune system without the need for ex vivo manipulation.

Headquartered in Cambridge, Massachusetts, we are led by an experienced management team and independent Board of Directors with deep expertise in immunology and immuno-oncology as well as the design and clinical development of protein biologics.

For more information, visit www.cuebiopharma.com and follow us on Twitter at https://twitter.com/CueBiopharma.

Investor Contact
George B. Zavoico, Ph.D.
VP, Investor Relations & Corporate Development
Cue Biopharma, Inc.
gzavoico@cuebio.com

Media Contact
Darren Opland, Ph.D.
LifeSci Communications
darren@lifescicomms.com

FAQ

When is Cue Biopharma's conference call scheduled?

Cue Biopharma's conference call is scheduled for May 17, 2021, at 4:30 p.m. EDT.

What is the focus of the upcoming conference call for Cue Biopharma?

The conference call will focus on a clinical update regarding the Phase 1a/1b trial of CUE-101 and recent business developments.

What significant update will Cue Biopharma provide during the call?

Cue Biopharma will report a confirmed partial response in a patient receiving CUE-101 for HPV+ recurrent/metastatic head and neck cancer.

How can investors access the Cue Biopharma conference call?

Investors can access the conference call via Cue Biopharma's website or by calling the provided phone numbers.

What is CUE-101 used for in Cue Biopharma's clinical trials?

CUE-101 is being investigated as a treatment for HPV+ recurrent/metastatic head and neck squamous cell carcinoma.